As the Canadian market navigates through a period of technological repricing, investors are reassessing valuations amidst concerns about AI-driven disruptions and increased capital spending in the tech sector. In this environment, identifying stocks that may be trading below their intrinsic value can offer opportunities for those seeking to balance potential risks with long-term growth prospects. Top 10 Undervalued Stocks Based On Cash Flows In Canada Name Current Price Fair Value (Est) Discount (Est) WELL Health Technologies (TSX:WELL) CA$4.05 CA$6.77 40.2% Pan American Silver (TSX:PAAS) CA$75.46 CA$131.70 42.7% Kits Eyecare (TSX:KITS) CA$20.20 CA$38.54 47.6% Haivision Systems (TSX:HAI) CA$8.40 CA$14.11 40.5% Gildan Activewear (TSX:GIL) CA$97.30 CA$162.22 40% Exchange Income (TSX:EIF) CA$98.63 CA$170.46 42.1% Decisive Dividend (TSXV:DE) CA$7.30 CA$13.96 47.7% Avino Silver & Gold Mines (TSX:ASM) CA$13.84 CA$23.22 40.4% Alamos Gold (TSX:AGI) CA$54.88 CA$105.60 48% Ag Growth International (TSX:AFN) CA$29.65 CA$49.27 39.8% Click here to see the full list of 23 stocks from our Undervalued TSX Stocks Based On Cash Flows screener. Here we highlight a subset of our preferred stocks from the screener. Endeavour Mining Overview: Endeavour Mining plc is a multi-asset gold producer operating in West Africa with a market capitalization of CA$18.91 billion. Operations: The company's revenue is derived from several mines in West Africa, with contributions of $1.03 billion from the Ity Mine, $516.60 million from the Mana Mine, $959.90 million from the Houndé Mine, $599.40 million from the Lafigué Mine, and $791.10 million from the Sabodala Massawa Mine. Estimated Discount To Fair Value: 27.2% Endeavour Mining appears undervalued based on discounted cash flow analysis, trading at CA$78.38, below its estimated future cash flow value of CA$107.68. Despite an unstable dividend track record, earnings are forecast to grow significantly at 36.9% per year, outpacing the Canadian market's growth rate of 12.5%. Recent results show increased production and a strong financial turnaround with net income improvements; however, rising all-in sustaining costs could impact future profitability margins. Upon reviewing our latest growth report, Endeavour Mining's projected financial performance appears quite optimistic. Take a closer look at Endeavour Mining's balance sheet health here in our report.TSX:EDV Discounted Cash Flow as at Feb 2026 Firan Technology Group Overview: Firan Technology Group Corporation manufactures and sells aerospace and defense electronic products and subsystems in Canada, the United States, and China, with a market cap of CA$377.60 million. Story Continues Operations: The company's revenue is derived from its Circuits segment, which generated CA$126.11 million, and its Aerospace segment, contributing CA$62.48 million. Estimated Discount To Fair Value: 20.2% Firan Technology Group is trading at CA$15, below its estimated future cash flow value of CA$18.8, suggesting it is undervalued by over 20%. Earnings are forecast to grow significantly at 20.8% annually, surpassing the Canadian market's growth rate of 12.5%. While revenue growth is slower than desired at 8.8% per year, it still exceeds the Canadian market average of 6.2%, highlighting potential for long-term value appreciation despite some growth constraints. Our expertly prepared growth report on Firan Technology Group implies its future financial outlook may be stronger than recent results. Dive into the specifics of Firan Technology Group here with our thorough financial health report.TSX:FTG Discounted Cash Flow as at Feb 2026 WELL Health Technologies Overview: WELL Health Technologies Corp. is a digital healthcare company focused on serving practitioners in Canada, the United States, and internationally, with a market cap of approximately CA$1.03 billion. Operations: The company generates revenue through various segments, including SaaS and Technology Services (CA$85.16 million), Canadian Patient Services - Primary WMC (CA$253.13 million), Canadian Patient Services - Specialized WDC (CA$160.98 million), WELL Health USA Patient Services - Primary WISP (CA$116.57 million), WELL Health USA Patient Services - Primary Circle Medical (CA$126.10 million), and WELL Health USA Patient Services - Specialized CRH Medical and Provider Staffing, which contribute CA$250.86 million and CA$190.80 million respectively. Estimated Discount To Fair Value: 40.2% WELL Health Technologies, trading at CA$4.05, is undervalued based on future cash flow estimates of CA$6.77. It trades 40.2% below its fair value and analysts anticipate a price increase of 87.3%. The company is poised for profitability within three years with earnings expected to grow by nearly 92% annually, outpacing the Canadian market's revenue growth rate of 6.2%. Recent credit facility expansion supports acquisition strategies and strengthens financial positioning. According our earnings growth report, there's an indication that WELL Health Technologies might be ready to expand. Get an in-depth perspective on WELL Health Technologies' balance sheet by reading our health report here.TSX:WELL Discounted Cash Flow as at Feb 2026 Taking Advantage Click this link to deep-dive into the 23 companies within our Undervalued TSX Stocks Based On Cash Flows screener. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Contemplating Other Strategies? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TSX:EDV TSX:FTG and TSX:WELL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
3 TSX Stocks Estimated To Be Trading Below Intrinsic Value By Up To 40.2%
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...